Oncology CRO & Drug Development Services
Medelis is a single-source provider for oncology CRO and oncology drug development services, providing a total solution for biotechnology and pharmaceutical companies seeking rapid drug development and approval. Our offerings include
- Oncology clinical trial management and design, including strategic plans for regulatory approval from Phase I through NDA
- Preclinical program analysis, design, management and execution
- Preclinical program review and "gap analysis"
- Site identification, qualification, management, contracting and payment
- Investigator identification & recruitment
- Patient recruitment & accrual strategies
- Project management & monitoring of clinical studies
- Early design and prototyping, simulation, preclinical and phase I-III clinical studies for medical device manufacturers
Learn more about our oncology CRO services »
World-Class Expertise
We specialize in oncology clinical trials, which are usually longer and more complex than those targeting other diseases. Medelis' medical founders, team physicians and clinical trial management physicians are internationally-recognized oncology thought and opinion leaders who understand the future of personalized medicine and threshold of credibility trials. Our extensive worldwide contacts and involvement with the oncology clinical research community keep us close to research trends and developments. And our entire management team, project managers and CRAs all have deep oncology experience to complement their operational and technical skills.
More about our focus on oncology & targeted therapeutics »
Clinical Answers Faster
Medelis has the breadth of capabilities, depth of expertise, strategic partnerships, focus and agility to deliver accurate results quickly. We create superior research designs that yield the right data the first time. And we're organized to set up trials and recruit patients with exceptional speed.
With this approach, we can deliver faster, more accurate results and help speed our clients' drugs to market.
Recent News: Medelis Publishes "Adaptive Trial Design in Phase I / Phase II Studies"
Cytel CEO Ranganath Nayak, PhD discusses how adaptive trial design benefits sponsors in phase I and phase II studies.
Phoenix AZ —February 2, 2010 — Medelis, Inc., a full-service oncology contract research organization (CRO) providing drug development services in the US and Europe, has published a free new issue of Peer Perspectives in Oncology, "Adaptive Trial Design in Phase I / Phase II Studies." In this interview, Cytel CEO Ranganath Nayak, PhD discusses the benefits, opportunities, and challenges presented by adaptive trial design in phase I and phase II studies.
"Cytel has designed more adaptive trials for industry sponsors than any other service provider and in virtually every therapeutic area," explains Medelis CEO Bob Bosserman."Sponsors should carefully consider the adaptive model for the many commercial, ethical, and budgetary benefits that the paper explores."
Oncology thought-leaders Dr. Alan Sandler and Dr. James Cassidy join Medelis’ Medical Advisory Board
Advisors provide cutting-edge expertise and assistance in the development and advancement of personalized therapies and further strengthen Medelis' relationship with the clinical research community.
Phoenix AZ —September 29, 2009 — Medelis, Inc., a full-service oncology contract research organization (CRO) providing drug development services in the US and Europe, today announced the addition of two respected oncology thought-leaders, Dr. Alan Sandler of Portland, Oregon and Dr. James Cassidy of Glasgow, Scotland, to its medical advisory board.
Alan Sandler, M.D. is a Professor of Medicine at Oregon Health & Science University. Board-certified in Medical Oncology and Internal Medicine, he specializes in cancer and blood disorders with a sub-specialty in lung cancer. He is widely considered a key opinion leader in the development of targeted therapies in the treatment of thoracic malignancies.
James Cassidy, MBChB, MD, MSc, FRCP is a leading researcher in anti-sickness compounds and innovative approaches to drug-resistant tumors. He is a Professor of Oncology and heads the Medical Oncology Department and the Division of Cancer Sciences & Molecular Pathology at the University of Glasgow, Scotland.
Medelis Expands CRO Services to Devices, Appoints Dr. Inder Makin as VP
Medelis will support device manufacturers throughout the product life cycle including early design and prototyping, simulation, preclinical and phase I-III clinical studies.
Phoenix AZ — September 22, 2009 — Medelis is pleased to announce that the company is expanding its services to support medical devices under the guidance of Inder Makin, M.D., Ph.D., who joins the company as Vice President, Devices & Radiological Health.
Dr. Makin has more than 20 years of experience developing "concept to clinic" healthcare technologies in both academia and industry. He has developed medical ultrasound-based research programs at various institutes, taking concepts (including catheter-based devices for intravascular thrombolysis transdermal drug delivery devices and non-invasive and intracorporeal tissue ablation devices) through feasibility and launch.
Cancer Researcher Dan Von Hoff, M.D. Advocates for “Context of Vulnerability,” A Powerful New Paradigm for Targeted Drug Development
Dr. Daniel Von Hoff and his team at TGen are fervent believers in a new approach to developing novel therapies for patients with pancreatic cancer. They are guided by a rationale dubbed the "context of vulnerability," which he explains in the latest issue of Peer Perspectives in Oncology.
Medelis has published a free new issue of Peer Perspectives in Oncology, "Context of Vulnerability: A Powerful New Paradigm for Targeted Drug Development." In this extensive interview, renowned oncology investigator Daniel D. Von Hoff, M.D., a founder of Medelis and a member the National Cancer Advisory Board, advocates for powerful new drug development paradigm that is generating impressive results in the war on pancreatic cancer, the most deadly of all cancers.
